Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

127.64
-3.4000-2.59%
Volume:486.61K
Turnover:62.76M
Market Cap:18.70B
PE:12.62
High:130.70
Open:130.27
Low:127.41
Close:131.04
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Oil companies, US big banks, fintechs

Reuters
·
04 Apr

Argus Downgrades Biogen to Hold From Buy

MT Newswires Live
·
04 Apr

BUZZ-US drugmakers fall after Trump's new tariff warnings

Reuters
·
04 Apr

Biogen downgraded to Hold from Buy at Argus

TIPRANKS
·
04 Apr

Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement

Simply Wall St.
·
04 Apr

Biogen : RBC Cuts Target Price to $221 From $225

THOMSON REUTERS
·
03 Apr

RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Biopharma Credit Plc - Receives $8.25 Million Settlement Payment From Biogen

THOMSON REUTERS
·
02 Apr

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Dow Jones
·
02 Apr

Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation

MT Newswires Live
·
02 Apr

BRIEF-Biogen’S Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation For The Treatment Of Alzheimer’S Disease

Reuters
·
02 Apr

Biogen’s Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
02 Apr

Biogen: Phase 2 Celia Study Is NOW Fully Enrolled, With a Data Readout Expected in 2026

THOMSON REUTERS
·
02 Apr

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

GlobeNewswire
·
02 Apr

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-04-01

Reuters
·
02 Apr

Organon Acquires Tofidence for Intravenous Infusion in US

MT Newswires Live
·
01 Apr

Organon & Co - to Pay Tiered Royalties and Milestone Payments to Biogen

THOMSON REUTERS
·
01 Apr

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years

Simply Wall St.
·
01 Apr

Biogen - Final Process for Ec Decision on Lecanemab’s Marketing Authorisation Application Underway

THOMSON REUTERS
·
01 Apr

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
01 Apr